BUZZ-Dexcom climbs after plans to revamp board panel with Elliott, bring 2 directors

DexCom, Inc.

DexCom, Inc.

DXCM

0.00

** Shares of Dexcom DXCM.O rise 3.7% at $59.99 premarket

** The medical device maker on Thursday said it agreed to collaborate with Elliott Investment Management, among its largest investors, to identify two new independent board members

** CEO Jake Leach said on an investor call that DXCM is focusing on refreshing its board and seeks to add independent directors with medtech and operations expertise

** With the additions, the board would have appointed six new independent directors since the beginning of 2023 - DXCM

** Adds that the existing Technology Committee on the board will now become the Operations and Innovation Committee

** As of last close, DXCM stock down 12.88% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.